8-K: Cyclo Therapeutics Extends Merger Agreement Deadline and Secures Additional $2 Million Funding from Rafael Holdings

Cyclo Therapeutics extends its merger agreement deadline with Rafael Holdings to March 31, 2025, and secures an additional $2 million in convertible promissory notes from Rafael.

Summary

• Cyclo Therapeutics, Inc. has amended its merger agreement with Rafael Holdings, Inc. to extend the deadline for the merger to March 31, 2025.
• The original merger agreement, announced on August 21, 2024, involved a merger with Rafael through two subsidiary entities.
• The company also entered into an Eighth Amended and Restated Note Purchase Agreement with Rafael, issuing a $2 million convertible promissory note.
• This note matures on March 31, 2025, and bears interest at 5% per annum.
• The proceeds from the note will be used for working capital and general corporate purposes.
• The company also amended prior convertible promissory notes held by Rafael to extend their maturity date from February 15, 2025, to March 31, 2025.
• Rafael Holdings already holds approximately 39.5% of Cyclo Therapeutics' outstanding common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company secured additional funding and extended the merger deadline, the continued reliance on Rafael and repeated amendments suggest underlying financial challenges.

Positives

• The extension of the merger agreement provides more time to finalize the deal.
• The additional $2 million in funding provides Cyclo Therapeutics with working capital.
• The extension of the maturity date on prior notes provides the company with more financial flexibility.

Negatives

• The continued reliance on Rafael Holdings for funding may indicate difficulty in securing financing from other sources.
• The repeated amendments to the note purchase agreement and promissory notes could signal ongoing financial challenges.

Risks

• The merger may still not be completed if the SEC does not declare the Form S-4 effective or if other conditions are not met.
• Failure to meet obligations under the notes could trigger an event of default and acceleration of debt.
• Continued losses and cash burn could lead to further dilution or financial distress.

Future Outlook

The company is focused on completing the merger with Rafael Holdings and utilizing the additional funding for working capital and general corporate purposes.

Management Comments

• There are no direct management quotes in the document, but the company's actions indicate a commitment to completing the merger and securing necessary funding.

Industry Context

The biotechnology industry often sees companies relying on strategic partnerships and funding from larger entities to advance their research and development efforts. This announcement reflects that trend.

Comparison to Industry Standards

• It is common for smaller biotech companies to seek funding from larger pharmaceutical or investment firms, similar to Cyclo Therapeutics' relationship with Rafael Holdings.
• Extending merger deadlines is not uncommon in complex transactions, especially when regulatory approvals are involved.
• Convertible notes are a typical financing instrument used by companies to raise capital, offering investors potential equity upside.

Related Party Transactions

• The issuance of the convertible promissory note and the amendment to the merger agreement are related-party transactions with Rafael Holdings, a significant shareholder.

Stakeholder Impact

• Shareholders: The merger could provide potential upside if the combined entity performs well.
• Employees: The merger could lead to changes in organizational structure and potential job impacts.
• Creditors: The additional funding and extended maturity dates provide some short-term financial stability.

Next Steps

• Obtain SEC approval for the Form S-4 registration statement.
• Fulfill the remaining conditions for the merger agreement.
• Utilize the $2 million in funding for working capital and general corporate purposes.

Key Dates